The spread of Amikeron is accelerating. How much protection can the COVID-19 vaccine play?
With more than 30 mutant amino acids on key proteins, the new coronavirus variant "Omikeron" was quickly designated by WHO as a "variant of concern" (VOC) once it was reported.
On December 15, it was learned from SINOVAC Coxing that the latest laboratory results showed that the Ami kerong virus strain had neutralizing antibody tests on 20 doses of 2 doses of coronaVac and 48 doses of coronaVac, and the positive rate of serum neutralizing antibodies after 20 doses of two doses of vaccines was 35% (7/20), and the positive rate of serum neutralizing antibodies after 48 doses of three doses of vaccine was 94%. （45/48）。 The results showed that the vaccination of the third dose of vaccine could effectively improve the ability of serum to neutralize the Aomi Kerong virus strain.
SINOVAC coxing is conducting further studies of serum at more post-immune time points and with different antibody levels to obtain a comprehensive evaluation of the effects of the Ami kerong virus strain on the vaccine.
The test results of the China Academy of Food and Drug Control (CHINA National Academy of Food and Drug Control) showed that after receiving 2 doses of inactivated vaccine, the neutralizing antibody titer of the pseudovirus against the Omikerong variant was only slightly lower than that of the prototype strain, and the titer of the neutralizing antibody was 10 times higher than that of the neutralizing antibody after the three-dose inactivated vaccine. Some insiders believe that as more and more studies prove the safety and efficacy of sequential vaccination of vaccines, this vaccination strategy may accelerate under the influence of the Omikeron variant.